Dr Sanjay Kumar Aggarwal, MD, PHD | |
600 N Wolfe St, Johns Hopkins University, Baltimore, MD 21287-0005 | |
(410) 948-2960 | |
Not Available |
Full Name | Dr Sanjay Kumar Aggarwal |
---|---|
Gender | Male |
Speciality | Pediatrics - Pediatric Emergency Medicine |
Location | 600 N Wolfe St, Baltimore, Maryland |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1144295577 | NPI | - | NPPES |
973504600 | Medicaid | MD | |
022004300 | Medicaid | MD |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | D0057140 (Maryland) | Secondary |
2080P0204X | Pediatrics - Pediatric Emergency Medicine | D57140 (Maryland) | Primary |
Entity Name | Johns Hopkins University |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, will host its eighth annual European Users Conference (EUC) April 21 - 22 at the Corinthia Hotel in Budapest, Hungary.
Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy.
Protein Metrics, Inc., a leading provider of software for rapid and thorough protein characterization, today announced the release of Byologic. Byologic software enables easy and convenient identification and quantification of sequence variants, protein modifications, and degradants down to trace concentrations.
Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery.
Arena Pharmaceuticals, Inc. announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Sanjay Kumar Aggarwal, MD, PHD Po Box 64316, Baltimore, MD 21264-4316 Ph: (410) 933-1241 | Dr Sanjay Kumar Aggarwal, MD, PHD 600 N Wolfe St, Johns Hopkins University, Baltimore, MD 21287-0005 Ph: (410) 948-2960 |
News Archive
Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, will host its eighth annual European Users Conference (EUC) April 21 - 22 at the Corinthia Hotel in Budapest, Hungary.
Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy.
Protein Metrics, Inc., a leading provider of software for rapid and thorough protein characterization, today announced the release of Byologic. Byologic software enables easy and convenient identification and quantification of sequence variants, protein modifications, and degradants down to trace concentrations.
Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery.
Arena Pharmaceuticals, Inc. announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy.
› Verified 6 days ago
Hilary Tamara Wolf, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-7373 Fax: 410-328-7305 | |
Dr. Carmel Bogle, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 1800 Orleans St, Baltimore, MD 21287 Phone: 443-287-0526 Fax: 410-955-0897 | |
Anna Eunjoo Choe, Pediatrics Medicare: Medicare Enrolled Practice Location: 615 N Wolfe St Rm Wb602, Baltimore, MD 21205 Phone: 410-955-3362 Fax: 410-614-1582 | |
Dr. Melissa Lauren Shapiro, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2411 W Belvedere Ave Ste 407, Baltimore, MD 21215 Phone: 410-601-8663 | |
Dr. Alexander James Jaksic, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 781-223-0948 | |
Adam J Spanier, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 300 Armory Pl, Baltimore, MD 21201 Phone: 410-225-8780 Fax: 410-225-8766 | |
Milagritos D Tapia, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-6749 Fax: 410-328-6136 |